Understanding Tagrisso Prescribing Information: A Guide for Patients and Healthcare Providers

As a patient or healthcare provider, understanding the prescribing information for Tagrisso can be challenging. Tagrisso is a medication used to treat patients with metastatic non-small cell lung cancer (NSCLC) that has a specific mutation called epidermal growth factor receptor (EGFR).

In this guide, we will break down the prescribing information for Tagrisso, including dosage, administration, side effects, and other important information that patients and healthcare providers should be aware of.

Dosage and Administration

Tagrisso is available as 40mg or 80mg tablets and is taken once daily with or without food. The recommended dosage for Tagrisso is 80mg daily for patients who have already been treated with EGFR tyrosine kinase inhibitors (TKIs) and 40mg daily for patients who have not been previously treated with EGFR TKIs.

If a patient misses a dose, they should take their next dose at their regular scheduled time. However, patients should not double their dose to make up for any missed doses.

Side Effects

Like all medications, Tagrisso can cause side effects. The most common side effects of Tagrisso include diarrhea, rash, nausea, fatigue, decreased appetite, and dry skin. In some cases, patients may experience more severe side effects such as interstitial lung disease, which can be life-threatening.

It is critical that patients taking Tagrisso report any side effects to their healthcare provider immediately. Depending on the side effects, the patient’s healthcare provider may adjust the patient’s dosage or switch the patient to a different medication.

Drug Interactions

Tagrisso may interact with other medications, so it is essential to inform your healthcare provider of any other medications you are taking, including prescription and non-prescription medications, vitamins, and herbal supplements.

Some medications that may interact with Tagrisso include certain antibiotics, antifungal medications, and HIV medications. Drug interactions can lead to increased side effects or reduce the effectiveness of Tagrisso.

Pregnancy and Breastfeeding

Tagrisso may harm a developing fetus, so it is essential to inform your healthcare provider if you are pregnant or plan to become pregnant. Women who are taking Tagrisso should also avoid breastfeeding as it may harm the infant.

Conclusion

In conclusion, Tagrisso is a medication used to treat metastatic non-small cell lung cancer with a specific mutation called EGFR. As a patient or healthcare provider, it is essential to understand the medication’s prescribing information, including dosage, administration, side effects, drug interactions, and pregnancy and breastfeeding information.

If you are a patient taking Tagrisso, it is essential to report any side effects to your healthcare provider immediately. As a healthcare provider, it is crucial to inform patients about the medication’s expected side effects, drug interactions, and pregnancy and breastfeeding information.

By understanding Tagrisso’s prescribing information, patients and healthcare providers can ensure they are using the medication safely and effectively.